Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPCOART, ElisabethSAAD, Everardo D.SHI, QianSOMMEIJER, Dirkje WillemienZALCBERG, John RaymondMAUGHAN, TimGOLDBERG, Richard M.SCHMOLL, Hans-JoachimPUNT, Cornelis J. A.CUTSEM, Eric VanDOUILLARD, Jean-YvesHOFF, Paulo MarceloTEBBUTT, Niall C.FUCHS, Charles S.FALCONE, AlfredoTOURNIGAND, ChristopheGRAMONT, Aimery DeSARGENT, Daniel J.BURZYKOWSKI, TomaszBUYSE, Marc E.2015-08-272015-08-272015JOURNAL OF CLINICAL ONCOLOGY, v.33, n.3, suppl.S, 20150732-183Xhttps://observatorio.fm.usp.br/handle/OPI/10227engrestrictedAccessTrial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.conferenceObjectCopyright AMER SOC CLINICAL ONCOLOGYOncology1527-7755